决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Novel syngeneic model of anti-mouse CLDN18.2 CAR -T therapy for gastric cancer demonstrates a synergy with TGF-β and PD-L1 inhibitors.
由于胃上皮特异性启动子罕见,可用于胃癌的同源小鼠细胞系模型非常少。
由于胃上皮特异性启动子罕见,可用于胃癌的同系小鼠细胞系模型非常有限。此类模型有助于研究免疫系统完整的肿瘤微环境,尤其是常使用免疫缺陷小鼠的CAR-T研究。为建立能忠实模拟人胃癌的小鼠细胞系,我们从一只Smad4、Trp53和Cdh1缺陷雌鼠胃内自发形成的胃癌中建立了S6M细胞系(Pdx-1-Cre;Smad4 F/F;Trp53 F/F;Cdh1 F/+)。S6M注射至同系小鼠后可稳定成瘤,其组织学和分子特征与人肠型胃腺癌相符。值得注意的是,S6M过表达claudin 18(CLDN18)的亚型2,这是人胃腺癌的重要分子治疗靶点。抗小鼠CLDN18.2 CAR-T细胞可抑制携带S6M同系移植瘤小鼠的肿瘤生长,但对CLDN18.2低表达的S1M细胞系则无此作用。联合抑制免疫抑制分子TGF-β和PD-L1,可通过招募NK细胞进入肿瘤微环境,增强抗小鼠CLDN18.2 CAR-T细胞对S6M细胞的体内疗效。这提示,这一新型同系胃癌细胞系模型可能有助于设计创新的临床治疗方案。
There are very few syngeneic mouse cell line models available for gastric cancer owing to the rarity of stomach epithelium-specific promoter. Mouse cell line models are useful to study an immunologically intact tumor microenvironment, especially in the setting of CAR-T studies that often use immunocompromised mice. To establish a mouse cell line faithfully recapitulating human gastric cancer, we generated the S6M cell line from an autochthonous gastric cancer formed in the stomach of a female mouse deficient in Smad4, Trp53 , and Cdh1 ( Pdx-1-Cre ; Smad4 F/F ; Trp53 F/F ; Cdh1 F/+ ). S6M readily formed a tumor when injected into syngeneic mice and demonstrated histologic and molecular features consistent with human intestinal gastric adenocarcinoma. Notably, S6M overexpressed the isoform 2 of claudin 18 (CLDN18.2), an important molecular therapeutic target in human gastric adenocarcinomas. Anti-mouse CLDN18.2 CAR-T cells suppressed tumor growth of mice bearing the syngeneic graft of S6M but not the CLDN18.2-low S1M cell line. Dual inhibition of immunosuppressive molecules TGF- and PD-L1 enhanced the in vivo efficacy of anti-mouse CLDN18.2 CAR-T against S6M cells by recruiting NK cells to tumor microenvironment, suggesting the potential utility of our novel syngeneic gastric cancer cell line model in designing innovative clinical therapeutic approaches.
MEMBER ACCOUNT
登录成功会直接打开下一页。